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1. Introduction
Cancer arises when a group of cells of a specific tissue type acquires genetic alterations which
allow them to grow in an uncontrolled manner eventually invading surrounding tissue
and/or traveling to other sites in the body disrupting the normal bodily functions and can
result in death. Often the type of acquired genetic alteration in the cancer cell is one which
causes the over or under production of a protein important to the regulation of cell growth, or
the production of a mutant form of such a protein that is overactive or less active (or not active)
or that has a different function than the normal form of the protein. This alteration in expression
pattern or altered function contributes to the cancerous state.
The science and art of molecular biology applied to tumor cell lines has provided much
information about how mutations contribute to the development of cancers. One group of
proteins that are often mutated in cancers are receptor tyrosine kinases. These proteins sit on
the cell surface and bind to molecules such as growth factors and result in the growth,
maintenance and multiplication of cells. When an activating mutation occurs in a receptor
tyrosine kinase the growth factor signal is no longer needed and the cell grows and multiplies
uncontrollably, contributing to a cancerous state. While mutations in receptor tyrosine kinases
has garnered much attention, and many drugs have been developed targeting them, these
kinases are by no means the only relevant kinase family to cancer.
In the past decade there has been rapid growth in the number of FDA approved cancer drugs
within the class known as kinase inhibitors. Some kinase inhibitors have become first line
targeted therapy for certain tumor types. For example, imatinib (Gleevec) is used effectively
to treat Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). The
Philadelphia chromosome encodes the mutant BCR-Abl kinase, an oncogenic driver for CML.
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Unfortunately, resistance to kinase inhibitors can develop through up-regulation of the target
kinase, or mutation of the target kinase resulting in decreased drug binding.
In the most ideal sense of targeted therapy for cancer, kinase inhibitors have the potential to
fulfill the goal of personalized cancer therapy. Studies have shown kinase inhibitors targeting
specific kinases that drive a proportion of patients’ tumors can provide better outcomes for
those patients. Combine this outcome with the possibility of mutant selective kinase inhibitors
which may leave tissue that expresses wild-type kinase largely unaffected and provide a
potentially better safety profile.
2. Kinase structure and function
Protein kinase function was first observed in 1954 by Burnett and Kennedy who discovered
an enzyme that phosphorylates casein [1]. Protein kinases are a group of protein enzymes that
phosphorylate protein and other targets in the cell in order to modulate these target proteins’
function. Protein kinases are often target proteins themselves. Protein kinases catalyze the
transfer of a phosphate group from adenosine triphosphate (ATP) to amino acid sidechains
that bear a hydroxyl group on target proteins, namely serine, threonine, and tyrosine. The
phosphorylation of one of these amino acid sidechains can drastically change the local
physicochemical environment as the relatively small polar unionized hydroxyl group is
transformed into the relatively large polar ionized phosphate group. This change in the local
environment can initiate a conformational change in the newly phosphorylated target protein,
in an attempt to find a new low energy conformation, which may modulate the function of the
target protein. The phosphorylation event may serve to activate or inhibit target protein
enzyme function, or simply modify the target proteins’ surface to modulate protein/protein
interactions. For example, Src homology 2 (SH2) domain containing proteins recognize certain
phospho-tyrosine sequences within protein targets which enable them to perform their
adaptor or scaffolding function [2].
Figure 1. The EGFR kinase domain with color coded structural elements. Cyan; N-terminal lobe. Red; C-terminal lobe.
Blue; P-loop. Magenta; hinge. Green; activation loop. Orange; catalytic loop.
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Protein kinases are classified into groups based on sequence similarity [3]. The AGC group is
named for protein kinases A, G and C. The CaM group is named for calcium/calmodulin-
dependent kinases. The CK1 group is named for casein kinase 1. The CMGC group is named
for cyclin dependent, mitogen-activated, glycogen synthase, and CDK-like kinases. The STE
group is named for sterile phenotype kinase. The TK group is named for tyrosine kinases, and
the TKL group is named for tyrosine kinase-like kinases. The groups are further broken down
to individual protein kinase families and these families may be further broken down to sub-
families. For example, within the TK group is the family called epidermal growth factor
receptor (EGFR) tyrosine kinase. The EGFR family includes members EGFR (Her1/ErbB1),
Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4. These family members have a high degree of
sequence similarity and function.
All protein kinases have a somewhat homologous kinase domain that adopts a common
tertiary structure [4]. Figure 1 represents the epidermal growth factor receptor (EGFR) kinase
domain and will serve to identify the various secondary structural elements of kinase domain
structure and function. Starting from the N-terminus, the basic structural elements of a kinase
domain include an N-terminal lobe, composed mostly of beta-sheet structure, and a C-terminal
lobe, composed mostly of alpha-helix structure. The two lobes are connected by a hinge region.
Of particular interest are the conserved mobile elements of the kinase domain which contribute
to kinase function.
Figure 2. EGFR kinase domain (ribbon) in the active conformation bound to an ATP analog (stick). The active confor‐
mation is characterized by alignment of key amino acid sidechains that form a hydrophobic spine (surface representa‐
tion).
Conformational mobility is essential for kinase function. A number of flexible loop regions are
important for the ability to interconvert between active and inactive conformations. These loop
regions include the activation loop (A-loop), catalytic loop, nucleotide binding loop (P-loop),
and the hinge region. The P-loop is a long loop that joins two anti-parallel beta-strands that
are a part of the N-terminal lobe beta-sheet structure of the kinase domain. This loop typically
contains a number of glycine residues that are able to access a large range of phi and psi angles
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and enable considerable conformational flexibility. In the inactive conformation the P-loop
may be largely disordered. In the active kinase conformation the P-loop may resemble more
of a classic beta-turn and is able to interact with the triphosphate group of bound ATP. The A-
loop includes one or more tyrosine residues that when phosphorylated induce the conversion
from the inactive to the active kinase conformation. The A-loop is long, containing around 27
amino acid residues that may fold into a number of isolated single turn helices. The A-loop
has a conserved DFG sequence, where in the non-phosphorylated inactive kinase conforma‐
tion the phenylalanine sidechain is oriented toward the triphosphate binding area of the ATP
binding site, the so called DFG-out conformation. In the phosphorylated active kinase
conformation, the DFG phenylalanine sidechain is oriented toward the interior of the protein,
the so-called DFG-in conformation [5-7]. While the DFG orientation related to active and
inactive kinase conformations is clear in some cases it is not clear in others, and is not as general
in differentiating active and inactive conformations as first thought. It has subsequently been
found through surface comparison of x-ray derived crystal structures of both active and
inactive forms of specific kinases, that the assembly of a hydrophobic spine through sidechain
interaction of discontiguous amino acids within the N-lobe, C-lobe and activation loop regions
offers a better structural definition of kinase activation for all kinase families [8]. Figure 2
demonstrates the hydrophobic spine assembly of a representative kinase. Both active and
inactive kinase conformations are able to bind ATP. However, only the active kinase confor‐
mation can perform the kinase function on substrates.
Protein kinases are important to many biological processes, as is evidenced by the more than
500 kinases encoded in the human genome. Kinases are involved in processes ranging from
modulation of intracellular trafficking of proteins, to assembly of complicated multiprotein
complexes, to gene expression. Kinase modulation of gene expression through signal trans‐
duction is of particular interest for cancer therapy.
The underlying cause of cancer is genomic instability. The emergence of a tumor cell typically
requires multiple mutations in the genome that both activate oncogenes and inactivate tumor
suppressor genes. These mutations synergize to transform a cell to a state of uncontrolled
growth, proliferation, and enhanced survival. Mutations and/or epigenetic alterations that
increase expression of, or produce constitutive active forms of some kinase proteins are known
to drive the proliferation and/or survival of some tumors [9]. The types of kinases that are often
mutated in tumor cells, although not exclusively, are found in signal transduction pathways.
These pathways are kinase cascades that transmit extracellular signals to the nucleus and
ultimately affect gene expression patterns. When a kinase in such a pathway is mutated where
it is constitutively active, the extracellular signal is no longer needed and the pathway is always
active and not regulated. Alternatively, epigenetic alterations or an increase in copy number
of a protein kinase gene may cause overexpression of the kinase to increase activation of a
signaling pathway. For example, a significant portion of non-small cell lung cancers (NSCLC)
over express or have EGFR mutations. This causes over active signaling through one or more
of the Ras/Raf/ERK, PI3K/AKT/mTOR, and STAT pathways that lead to increased growth,
proliferation, motility and survival of the tumor cells.
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The KIT receptor tyrosine kinase, or stem cell factor receptor, is a good example for represent‐
ing the different types of mutations that occur in kinases that contribute to the development
of cancer. KIT possesses an extracellular domain, a juxtamembrane domain, and a kinase
domain. Point mutations have been observed to occur in all domains of KIT [10]. The most
common mutations occur in the juxtamembrane domain followed by the extracellular domain,
and finally the kinase domain. Within the kinase domain mutations occur within the ATP
binding site and the activation loop. Multiple muatations may occur within a tumor cell. All
of these mutations produce constitutive active KIT. For example, juxtamembrane mutations
result in the disruption of the autoinhibited form of the kinase, which results in a similar
conformation to the phosphorylated activated kinase [11] Additionally, a KIT isoform with a
GNNK insert in the extracellular domain has been identified that, once phosphorylated
remains so for longer than the isoform that does not contain this insert, increases survival of
myeloma cells [12, 13]. Overexpression of wildtype KIT may also drive tumor development.
Overexpression may be due to an increase in gene copy number and/or hypomethylation of
the gene promoter region.
The link between the development of some tumors, and aberrant modulation of certain protein
kinases-either wildtype of mutant- has been established. Some of these aberrations, such as
the BCR-Abl protein, represent driver mutations that have lead to the successful translation
of experimental protein kinase inhibitors into the clinic for therapeutic treatment of cancer
patients.
3. Kinase inhibitors
The natural product staurosporin was one the first small molecules discovered that inhibits
the function of protein kinases [14]. Staurosporin is a non-selective inhibitor and is not
amenable to development as a drug. However, one staurosporin-like molecule, midostaurine
is in clinical development for oncology indications such as indolent systemic mastocytosis [15].
Imatinib, the first marketed kinase inhibitor for treatment of cancer, was discovered by scientist
at Ciba-Geigy in the 1990s. It was determined that imatinib inhibited the function of the BCR-
Abl fusion kinase that drives chronic myeloid leukemia [16]. Since this time (and perhaps
before) the primary rational approach to design of kinase inhibitors has been to target the ATP
binding site. The first experimentally determined structure of a small molecule bound to the
ATP binding site of a kinase appeared in the year 2000 [17]. This structure was groundbreaking,
in that it showed imatinib to be buried deeply in the ATP binding site of the kinase thus locking
it in an inactive conformation. This structure provided data that could be used for a structure
based design approach of future kinase inhibitors. The structure revealed a pose of imatinib
in the ATP binding site that is today designated the type II binding mode.
Clinically used ATP site binding direct kinase inhibitors fall within two categories that describe
their binding modes. Type I inhibitors may bind both active and inactive conformations of a
particular kinase target. Type II kinase inhibitors bind only inactive conformations of a kinase.
Both type I and II inhibitors bind in the ATP binding site and make use of hydrogen bonds to
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the amide backbone of hinge region amino acid residues. The difference between type I and
II inhibitors is that type II inhibitors typically penetrate deeper into the pocket accessing what
is termed an allosteric binding site, the effect of which is to displace the C-helix and locking
the kinase in an inactive conformation. Knowledge of binding geometries has been applied to
kinase inhibitor design projects.
The majority of kinase inhibitor design projects have focused on ATP competitive inhibi‐
tors  targeting the ATP binding site.  The popularity  of  such programs have spurred the
growth of  contract  research screening services  that  screen potential  inhibitors  in  a  high
throughput format for binding to the ATP binding site and/or inhibition of target kinase
function  [18].  Design  programs  may  be  conducted  in  a  variety  of  manners  from  high
throughput  screening of  compound libraries  to  fragment  based and/or  structure  guided
design. One approach is to start from known privileged fragments or templates - chemi‐
cal moieties that appear in numerous kinase inhibitors - such as the quinazoline ring system
[19]. The quinazoline ring system appears in many experimental kinase inhibitors, clinical
candidates (tandutinib), and kinase inhibitor drugs such as afatinib, vandetinib, lapatinib,
erlotinib and gefitinib (see Table 1).
Figure 3. Kinase hinge peptide backbone (A) hydrogen bonding pattern to ATP heterocycle (B) and other heterocycles
found in drug molecules. (C) quinazoline, e.g. erlotinib. (D) pyridine, e.g. imatinib. (E) pyrrolopyridine, e.g. vemurafe‐
nib. Dashed lines represent hydrogen bonds.
It appears that a unifying characteristic of kinase inhibitors that bind to the ATP binding site
is a heterocyclic moiety that serves as a mimic of the adenine ring system and forms Van der
Waals contacts with hydrophobic groups of the floor and ceiling of the ATP binding site as
well as one or more hydrogen bonds with the amide backbone of hinge region amino acid
residues. Figure 3 describes how ATP and some heterocycles found in kinase inhibitors form
their hydrogen bonding patterns to the hinge region. Because the ATP binding site is conserved
among kinases, kinase inhibitors tend to be promiscuous and inhibit numerous kinases other
than their primary target. How the final kinase inhibitor is adorned about its hinge binding
moiety contributes to its overall shape and possible intermolecular interactions, ultimately
determines its degree of selectivity for its intended target.
Another unifying theme of kinase inhibitors is that their binding to their kinase targets
displaces the alignment of the hydrophobic spine that is formed by kinase activation [8].
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Besides the occupation of the ATP binding site by the kinase inhibitor, disallowing binding
and use of ATP, the kinase inhibitor disrupts the formation of the hydrophobic spine necessary
for attainment of the active conformation (Figure 4). This observation leads to the inevitable
question of whether inhibitors, that disrupt the hydrophobic spine, but do not bind to the ATP
binding site, may be developed.
Considering the mountain of published research and plethora of X-ray diffraction and NMR
derived structures of kinase inhibitors bound to their target kinases, the design of kinase
inhibitors is fairly well understood. The remaining challenges for drug designers, in the area
of kinase inhibitors, are concerned with selectivity. Selectivity is a potential problem for kinase
inhibitors, thus far, because most target the highly conserved ATP binding site. Targeting a
single family of kinases, let alone a single member of a family, is difficult because of the inherent
promiscuity of this drug class. An even more difficult challenge is targeting a cancer relevant
mutant kinase selectively with respect to the wild type kinase. The selective targeting of a
mutant kinase that drives the proliferation and survival of a patients’ tumor has great promise
not only in potential survival benefit but also reduction in drug side effects.
Figure 4. EGFR kinase domain (ribbon) bound to kinase inhibitor lapatinib (stick). Note that the amino acid sidechains
that form the hydrophobic spine (surface) are bowed out of alignment.
Common side effects caused by kinase inhibitors include rash, fatigue, and gastrointestinal
disturbances such as nausea, vomiting, diarrhea, or constipation. For example, patients
receiving therapy with EGFR inhibitors may experience severe acneiform eruption and
diarrhea which may be dose limiting [20]. Additionally, the EGFR inhibitor gefitinib has been
associated with interstitial lung disease, especially in patients with underlying pulmonary
diseases [21]. The more promiscuous kinase inhibitors such as sunitinib and sorafenib exhibit
some cardiotoxicites such as hypertension, LVEF and QT prolongation [22]. Additional less
severe side-effects may be experienced by patients receiving kinase inhibitors such as hair
depigmentation which accompanies KIT inhibitors [23]. Even though kinase inhibitors are
considered targeted therapy the patient will experience side effects that can be associated with
the mechanism of action, off target effects and intrinsic chemical effects. Almost as common
as side effects are associated with anticancer drugs so is tumor resistance. And just as other
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anticancer drugs may encounter tumor resistance, a kinase inhibitor may also encounter
resistance either acquired or intrinsic.
Tumor resistance to anticancer drugs can be a challenging battle even though a lot has been
learned about the mechanisms that allow tumor cells to escape the chemical assault. One major
mechanism of tumor resistance to kinase inhibitors is mutant forms of the target kinase, either
preexisting or acquired during or after treatment, that reduce the kinase inhibitors binding
affinity. Early clinical experience with imatinib identified patients that developed resistance
after an initial response to the drug due to mutation of the ACR-Abl kinase that prevented
imatinib binding [24, 25]. Experience with KIT inhibitors has revealed drug resistant mutations
in this kinase [10]. Pharmacokinetic mediated tumor resistance to kinase inhibitors include,
polymorphisms in drug metabolizing enzymes and transporters. For example, CML patients
with low human organic cation transporter-1 (hOCT1) activity have suboptimal response to
imatinib but not to nilotinib [26, 27]. Other mechanisms of tumor resistance to kinase inhibitors
may include unique features of the tumors microenvironment and activation of alternative
signaling pathways. For a more comprehensive discussion of tumor resistance to kinase
inhibitors the reader is directed to the references [28, 29].
Since the year 2001 there have been no less than 24 small molecule, ATP site binding kinase
inhibitors approved by the USFDA for oncology indications (Table 1). As the concept of
oncogene addiction is explored more and a better understanding of the role of kinases in
oncology is realized, the class of kinase drugs may be ideally situated to have a profound effect
on personalized cancer medicine.
Structure Generic Name Target(s) Indication(s)
afatinib EGFR NSCLC
axitinib VEGFR 1/2/3 RCC
bosutinib BCR-Abl, Hck, Lyn,Src CML
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Structure Generic Name Target(s) Indication(s)
cabozantinib
RET, MET, VEGFR
1/2/3, KIT, TRKB,
Flt-3, AXL, TIE-2
MTC
ceritinib ALK, IGF-1R, InsR,ROS1 ALK-positive NSCLC
crizotinib ALK, c-Met, ROS ALK-positive NSCLC
dabrafenib B-RAF melanoma
dasitinib
BCR-Abl, SRC, LYN,
YES, FYN, KIT,
EPHA2, PDGFRb
CML
erlotinib EGFR NSCLC, pancreaticcancer
gefitinib EGFR NSCLC
Kinase Inhibitors — Targeted Personalized Cancer Therapy 9
Structure Generic Name Target(s) Indication(s)
ibrutinib BTK CLL, mantle celllymphoma
imatinib BCR-Abl, PDGFR,KIT
CML, ALL, GIST,
ASM
lapatinib EGFR, ERBB2 Breast cancer
nilotinib BCR-Abl, PDGFR CML
nintedanib VEGFR, FGFR,PDGFR IPF
pazopanib
VEGFR, PDGFR,
FGFR, KIT, Lck, FMS,
ITK
RCC, soft tissue
sarcomas
ponatinib
BCR-Abl, VEGFR,
PDGFR, Src, KIT, Flt3,
RET, Tie2
CML, Ph+ All
regorafenib
VEGFR, BCR-Abl, B-
Raf, PDGFR, FGFR,
Tie2
CRC
ruxolitinib JAK myelofibrosis
sorafenib Multi-kinase inhibitor RCC, DTC
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Structure Generic Name Target(s) Indication(s)
sunitinib Multi-kinase inhibitor
RCC, GIST, pancrease
cancer, neuro-
endocrine tumors
trametinib MEK melanoma
vandetanib EGFR, VEGFR, RET,Brk, Src, Tie2 MTC
vemurafenib Raf kinases melanoma
Table 1. USDA approved kinase inhibitors for oncology indication.
4. Personalized medicine and kinase inhibitors
The basic concept of personalized cancer medicine is to match the patient with an appropriate
therapeutic regimen that will provide the best outcome [30]. This can be accomplished on a
variety of different levels. With regard to a pharmacological approach, the traditional way
patients are assigned to therapy is based on tumor type, that is, what anatomical site at which
the tumor resides and/or what type of histopathology the tumor cells derive from. Once these
pieces of information were obtained the patient would be assigned a pharmacotherapy
regimen that provided the best statistical outcome based on collective experience. This
approach has worked as well as can be expected, and exceedingly well in some tumor types
considering the diseases’ high mortality. However with modern scientific advances and strive
toward better outcomes, an even more personalized approach has emerged.
A modern approach to personalized cancer pharmacotherapy can be considered on three basic
levels which can be applied individually or combined. These three levels are the patient’s
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pharmacogenetics, the tumor’s genomics and/or proteomics, and the tumor’s response to drug
exposure. Patient pharmacogenetics refers to the patients genetics that are relevant to effects
on pharmacokinetics of drugs, for example, polymorphisms in drug metabolizing enzymes.
Tumor genomics and/or proteomics refers to specific genetic abnormalities that effect specific
gene expression and is thought to contribute to tumor development or maintenance. The
application of any or all of these pieces of information may improve the outcome of pharma‐
cotherapy for the patient.
The application of pharmacogenomics to personalized therapy can be exemplified by appli‐
cation to tamoxifen therapy for the breast cancer patient. Tamoxifen acts as an anti-estrogen
on breast tissue and is used for treatment of estrogen receptor positive (ER+) breast cancer. It
has been determined that tamoxifen is converted in vivo to 4-hydroxytamoxifen, which is a
much more active anti-estrogen agent. It was subsequently found that this transformation is
accomplished by the drug metabolizing enzymes cytochrome P-450 (CYP) isofroms 2D6 and
2C19 [31]. Patients that were receiving tamoxifen therapy and concurrently receiving selective
serotonin reuptake inhibitor (SSRI) drugs, known to inhibit CYP 2D6, experienced poor
outcomes because of the failure to convert tamoxifen to 4-hydroxtamoxifen. A significant
percentage of the population carry a genetic polymorphism in the CYP 2D6 gene which results
in poor metabolism with respect for the CYP 2D6 isoform and will not receive the full benefit
of tamoxifen therapy [32]. Consequently a readily available genomic test is available for
patients that can identify those who are not good candidates for tamoxifen therapy, because
they have a specific 2D6 polymorphism, so that they can be directed to alternatives.
Advances in genomics and proteomics have enabled selection of patients that may benefit from
targeted therapies for certain tumor types. Analysis of tumor cells on the protein level using
immunohistochemistry (IHC) can identify cells that express relevant protein targets. An
example of the application of this approach is the detection of c-erbB2 (Her2/Neu) receptor in
breast cancer patients which can direct them toward trastuzumab therapy. Specific gene
mutations in tumor cells may be detected using techniques of RT-PCR, DNA microarray, and
fluorescence in situ hybridization (FISH) that can be used to direct patients to therapy that
may be beneficial. For example, a study demonstrated the utility of screening non-small cell
lung cancer patients for amplification of the epidermal growth factor receptor (EGFR). Patients
with amplified EGFR receiving an EGFR kinase inhibitor (gefitinib) had longer median
progression free survival (PFS) and overall survival (OS), compared to those who did not have
amplified EGFR [33, 34]. Furthermore, of those patients who responded to gefitinib therapy
77% had EGFR gene amplification, whereas only 33% of non-responders had EGFR gene
amplification. This study demonstrates the utility of identifying patients with mutations that
drive tumor growth and survival and matching them with appropriate targeted therapy. The
study also highlights the shortcoming of single gene determination directed therapy in that
33% of non-responders also had EGFR amplification.
A potentially more invasive and perhaps technically challenging approach is to directly test
samples of the patient’s tumor against available drugs. This approach of using personalized
xenografts to direct patient therapy was demonstrated in a patient with advanced pancreatic
patient [35]. After initial surgery metastases were discovered and adjuvant gemcitabine
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therapy failed to halt progression. A personalized mouse xenograft model was developed from
the patient’s tumor tissue and was found to respond to the DNA alkylating agents, mitomycin
C and cisplatin. The patient was assigned to mitomycin C treatment and subsequently cisplatin
and achieved a partial response with duration of 50+ months. Genomic analysis of the patient’s
tumor tissue revealed inactivation of the PALB2 gene, which is involved with repair of double
strand DNA breaks. It seems logical that the patient’s tumor responded to the DNA alkylating
agents that would cause double stranded DNA breaks.
The genomic approach has been applied to kinase inhibitors from the beginning of their
introduction to the arsenal of pharmacotherapy options. Imatinib, the first kinase inhibitor to
be marketed is targeted at a specific genomic alteration, a chromosomal translocation produc‐
ing the Philidelphia chromosome (Ph) that expresses a mutant gene product, the BCR-Abl
kinase. This kinase is constitutively active, and is the driver of nearly all chronic myeloid
leukemias (CML). Therefore, patients with CML and are Ph+ can be matched to imatinib
therapy. Imatinib therapy has been fairly successful for CML patients. It has been shown that
patients who achieve complete cytogenic response at 2 years on imatinib therapy tend to
maintain the durable response and do not have mortality significantly different than the
general population [36].
Because the effectiveness of kinase inhibitors require that the target kinase to be a driver of,
expressed in, or aberrantly expressed in, or be mutated in the tumor cells, it is important to
know the status of the target within the specific patient’s tumor in order to best assign the
patient to kinase inhibitor therapy. To this end specific diagnostic tests have been developed
to help guide selection of kinase inhibitor therapy. Indeed, twelve of the approved kinase
inhibitors’ prescribing information assume diagnostic testing be performed, and of those, four
require a diagnostic test for prescription. Table 2 lists six such diagnostics recognized by the
USFDA [37].
5. Emerging kinase targets
Because kinase enzymes are involved in numerous biological processes it is not surprising that
many of them have become therapeutic targets for various disease sates including cancers. As
noted above, drug development of kinase inhibitors for oncology indications has accelerated
in the last decade with no sign of slowing. This acceleration has been spurred by emergent
technologies and advances in molecular and systems biology, proteomics, and genomics. The
continued advancement of understanding of the molecular changes that occur in the devel‐
opment of a cancer has helped identify likely therapeutic targets. Some of the more recently
identified targets include the BTK, CDK8, and DNA-PK.
Although a Bruton’s tyrosine kinase (BTK) inhibitor (ibrutinib) was recently approved for
clinical use, BTK is a relatively new kinase target. BTK plays a role in B-cell receptor signaling,
proliferation, differentiation, and survival. Ibrutinib works by irreversible inhibition of BTK
through covalent modification of the enzyme. In a clinical trial in mantle cell lymphoma (MCL)
patients, who had three prior therapies, an overall response rate of 69% and a progression free
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survival of 13.9 months were observed. Ibrutinib is approved for second line treatment of MCL
and chronic lymphocytic leukemia (CLL) [38].
Drug (generic name) Diagnostic Product Diagnostic Product Use
afatinib Therascreen EGFR RGQ PCR Kit Detects EGFR exon 19 deletions and
exon 21 substitution mutations.
Intended for selection of NSCLC
patients who may benefit from afatinib
therapy.
crizotinib VTSIS ALK Break Apart FISH Probe
Kit
Detection of ALK gene
rearrangements.
Prescription use only, intended for
selection of NSCLC patients eligible for
crizotinib treatment.
dabrafenib and tramatenib THxID BRAF Kit Detection of BRAF(V600E) and (V600K)
mutations in melanoma tissue.
Intended to aid selection of melanoma
patients who may benefit from
treatment with dabrafenib and/or
trametinib.
erlotinib Cobas EGFR Mutation Test Detects EGFR exon 19 deletions and
exon 21 substitution mutations.
Intended for selection of patients with
metastatic NSCLC who may benefit
from afatinib therapy.
imatinib mesylate DAKO C-KIT PharmDx Quantitative c-Kit detection in GIST
and normal tissues. Intended to aid
selection of GIST patients who may be
eligible for imatinib mesylate
treatment.
vemurafenib COBAS 4800 BRAF V600 Mutation TestDetection of BRAF (V600E) mutation in
melanoma. Intended to aid selection of
melanoma patients who may benefit
from vemurafenib therapy.
Table 2. US FDA Cleared or Approved In Vitro Companion Diagnostic Tools for Kinase Inhibitors.
Cyclin dependent kinase 8 (CDK8) was recently identified as a colorectal cancer oncogene [39].
It was discovered that 47% of colorectal cancer samples demonstrated copy number gain of
the chromosomal region carrying the CDK8 gene. It has also been shown that 76% of colorectal
cancers showed positive expression of nuclear CDK8, and that increased positive expression
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rate correlated with increased clinical stage [40]. Additionally, expression of CDK8 trans‐
formed NIH 3T3 cells, however a kinase inactive version did not. Experimental knockdown
of CDK8, in colorectal cancer cell lines with high CDK8 expression levels, induced a decrease
in cell proliferation. While most CDKs regulate cell cycle progression CDK8 and some others
play a role in transcription regulation. Assembly of CDK8 with other key protein partners
forms a mediator complex which can activate β-catenin dependent transcription. Furthermore
it was shown that CDK8 function represses E2F1 activity, a known negative regulator of β-
catenin [41]. Of note is the fact that knockdown of CDK8 in some colorectal cancer cell lines
does not completely diminish β-catenin levels, which suggests that other genetic determinants
of resistance must be identified to exclude patients that would not benefit from a future CDK8
targeted therapeutic.
DNA-dependent protein kinase (DNA-PK) is another emerging oncology kinase target. Being
that the development of cancer is due to genomic instability that results in the acquiring of
genetic mutations that drive tumor formation, it should be no surprise that tumor cells may
have defective DNA repair pathways that result in a mutator phenotype. It is no wonder that
the first class of anti-cancer drugs were DNA alkylating agents that cause irreparable damage
to DNA of tumor cells, although with severe side effects and risk of secondary tumors arising
from DNA damaged normal cells. A less devastating targeted approach to induce irreparable
DNA damage in tumor cells, while sparing normal cells, is to target still operating DNA repair
pathways that are critical to the tumor cells survival. In other words disable a DNA repair
pathway that will synergize with an already disabled pathway. For example, DNA-PK is
critical for repairing double strand DNA breaks through the non-homologous end joining
(NHEJ) pathway. A second pathway for repairing double strand breaks is the homologous
recombination pathway, which is impaired in tumor cells with mutations in genes such as
BRCA1 and BRCA2 as well as others. Targeting tumors with impaired homologous recombi‐
nation by inhibiting the NHEJ pathway with DNA-PK inhibitors should, in theory, cause
activation of cell death pathways as double strand DNA-breaks build-up in the cells [42, 43].
Normal cells should be able to withstand the assault due to both pathways being operable.
6. Summary
Kinase inhibitors have enormous potential to facilitate improved outcomes for some cancer
patients especially in the context of personalized medicine. The personalized approach that
implements genomic analysis to identify potential driver kinases in patient tumor samples will
enable matching the patient with the best kinase inhibitor for the best outcome. The identifi‐
cation of drug resistant mutations in the targeted kinase will be critical in order to avoid
treatment that is not likely to be beneficial to the patient. Also critical, is the identification of
relevant polymorphisms in drug metabolizing enzymes and transporters that may affect
pharmacokinetics of the kinase inhibitor, in order to assure adjustments are made to achieve
optimum drug exposure. These considerations along with proper management of side effects
can maximize patient benefit from targeted personalized cancer therapy with kinase inhibitors.
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Nomenclature
ALL-acute lymphoblastic leukemia; ASM-aggressive systemic mastocytosis; CLL-chronic
lymphocytic leukemia; CML-chronic myeloid leukemia; CRC-colorectal cancer; DTC-differ‐
entiated thyroid carcinoma; GIST-gastrointestinal stromal tumor; IPF-idiopathic pulmonary
fibrosis; MTC-medullary carcinoma of the thyroid; NSCLC-non-small-cell lung cancer; RCC-
renal cell carcinoma.
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